Literature DB >> 30887729

Beta-blocker use is an independent risk factor for thunderstorm asthma.

Ron V Sultana1,2, Dean P McKenzie3,4, Michael T Fahey4, Michael Sutherland2,3, Vasilios Nimorakiotakis1,2.   

Abstract

OBJECTIVE: To identify risk factors for thunderstorm asthma (TA) in subjects ≥15 years of age from information available in routine clinical records.
METHODS: Retrospective and hospital-based case-control study of various clinical factors in all TA cases (n = 53) who presented to a single-site ED in November 2016 (TA16) and in a control group of patients (n = 156) who presented to the same ED with asthma during the pollen season over eight non-TA years. Bivariate analysis and multivariable logistic regression modelling was performed to calculate the odds of TA asthma in the presence of potential risk factors.
RESULTS: A logistic regression model revealed that the odds of TA were lower for age (odds ratio [OR] 0.97, 95% confidence interval [CI] 0.95-0.99), higher for Asian country of birth (OR 4.09, 95% CI 1.40-11.95) and higher for oral beta-blocker use (OR 6.43, 95% CI 1.58-26.33) compared to controls. No difference was found between TA16 cases and controls for allergies (to medication, grass pollen, animal), hayfever, smoking, oral non-steroidal anti-inflammatory drugs, or aspirin. Newly diagnosed asthma was higher in TA16 cases versus controls (32.1% vs 12.2%, P = 0.001).
CONCLUSIONS: Oral beta-blocker medications, younger age and Asian-born heritage are risk factors for TA. Further study is required to explore the potential association between beta-blockers and TA.
© 2019 Australasian College for Emergency Medicine.

Entities:  

Keywords:  Australia/epidemiology; adrenergic beta-antagonists/adverse effect; allergens/adverse effect; asthma/aetiology; asthma/drug therapy; asthma/epidemiology

Year:  2019        PMID: 30887729     DOI: 10.1111/1742-6723.13275

Source DB:  PubMed          Journal:  Emerg Med Australas        ISSN: 1742-6723            Impact factor:   2.151


  1 in total

Review 1.  The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports.

Authors:  Miriam Bennett; Catherina L Chang; Michael Tatley; Ruth Savage; Robert J Hancox
Journal:  ERJ Open Res       Date:  2021-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.